plavix has been researched along with tetracycline in 1 studies
Studies (plavix) | Trials (plavix) | Recent Studies (post-2010) (plavix) | Studies (tetracycline) | Trials (tetracycline) | Recent Studies (post-2010) (tetracycline) |
---|---|---|---|---|---|
7 | 0 | 5 | 21,524 | 977 | 3,656 |
Protein | Taxonomy | plavix (IC50) | tetracycline (IC50) |
---|---|---|---|
90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | 22.4474 | |
heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | 22.4474 | |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | 8.33 | |
30S ribosomal protein S6 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S7 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L15 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L10 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L11 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L7/L12 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L19 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L1 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L20 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L27 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L28 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L29 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L31 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L31 type B | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L32 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L33 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L34 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L35 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L36 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S10 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S11 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S12 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S13 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S16 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S18 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S19 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S20 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S2 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S3 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S4 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S5 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S8 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S9 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L13 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L14 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L16 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L23 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S15 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L17 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L21 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L30 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L6 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S14 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S17 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S1 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L18 | Escherichia coli K-12 | 4.58 | |
Alpha-synuclein | Homo sapiens (human) | 6.06 | |
50S ribosomal protein L2 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L3 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L24 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L4 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L22 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L5 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S21 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L25 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L36 2 | Escherichia coli K-12 | 4.58 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for plavix and tetracycline
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |